Home | Business News | Browse by Publication | F | Fair Disclosure Wire

Q3 2008 CIPHER PHARMACEUTICALS INC Earnings Conference Call - Final.

Article Excerpt
OPERATOR: Welcome to the Cipher Pharmaceuticals fiscal 2008 third quarter conference call. (OPERATOR INSTRUCTIONS) As a reminder, this conference is being recorded day, Friday, November 7, 2008. On behalf of the speakers that follow, listeners are cautioned that today's presentation and the responses to questions may contain forward-looking statements within the meaning of the Safe Harbor provisions of the Canadian provisional securities laws. Forward-looking statements involve risks and uncertainties and undue reliance should not be placed on such statements.

Certain material factors or assumptions are implied in forward-looking statements and actual results may differ materially from those expressed or implied in such statements. For additional information about factors that may cause actual results to differ materially from expectations and about material factors or assumptions applied to making forward-looking statements, please consult the MD&A for this quarter when available to you. The risk factor section of the annual information form and Cipher's other filings with Canadian Securities Regulators. Cipher does not undertake to update any forward statements. Such statements speak only as of the date made.

I would now like to turn the conference over to Mr. Larry Andrews, President and Chief Executive Officer of Cipher Pharmaceuticals. Please go ahead.

LARRY ANDREWS, PRESIDENT, CEO, CIPHER PHARMACEUTICALS INC: Thank you, Operator. Good morning and thank you for participating in today's conference call. Joining me today is Norm Evans, our Chief Financial Officer. Earlier this morning we released our financial results for Q3, 2008, and if you did not receive a copy of the press release, please visit our website at www.cipherpharma.com. On today's call we will review our financial results for the quarter and provide an update on our drug development activities. After that, we'll open the call to your questions. Norm will first review the financial results. Norm.

NORM EVANS, CFO, CIPHER PHARMACEUTICALS INC: Thank you, Larry. Good morning, everyone. I'll cover the key financial highlights for the quarter. In the third quarter we recorded total revenue of $0..7 million, a significant increase over...

View this article FREE - Now for a Limited Time, try Goliath Business News
Free for 3 Days!